D. E. Shaw & Co., Inc. X Biotech Inc. Transaction History

D. E. Shaw & Co., Inc.

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Feb 14, 2023	SELL	$3.03 - $3.79 $100,283 - $125,437	-33,097 Reduced 68.74%	15,052 $52,000
Q3 2022 Nov 14, 2022	BUY	$3.58 - $5.88 $45,892 - $75,375	12,819 Added 36.28%	48,149 $175,000
Q2 2022 Aug 15, 2022	BUY	$5.13 - $9.2 $181,242 - $325,036	35,330 New	35,330 $199,000
Q1 2022 May 16, 2022	SELL	$8.64 - $11.71 $95,402 - $129,301	-11,042 Closed	0 $0
Q4 2021 Feb 14, 2022	SELL	$10.95 - $16.07 $57,377 - $84,206	-5,240 Reduced 32.18%	11,042 $123,000
Q3 2021 Nov 15, 2021	SELL	$12.95 - $18.24 $60,178 - $84,761	-4,647 Reduced 22.2%	16,282 $211,000
Q2 2021 Aug 16, 2021	BUY	$15.83 - $17.84 $55,515 - $62,564	3,507 Added 20.13%	20,929 $347,000
Q1 2021 May 17, 2021	BUY	$15.92 - $20.3 $277,358 - $353,666	17,422 New	17,422 $299,000
Q2 2020 Aug 14, 2020	SELL	$10.39 - $16.07 $292,010 - $451,647	-28,105 Closed	0 $0
Q1 2020 May 15, 2020	SELL	$8.89 - $24.94 $1.31 Million - $3.68 Million	-147,684 Reduced 84.01%	28,105 $298,000
Q4 2019 Feb 14, 2020	BUY	$8.33 - $19.95 $1.46 Million - $3.51 Million	175,789 New	175,789 $3.28 Million

4.87M

Ticker XBIT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 30,439,300
Market Cap $114M
Description
XBiotech Inc., a biopharmaceutical company, discovers, develops, and commercializes True Human monoclonal antibodies for treating various diseases. The company focuses on developing a pipeline of product candidates targeting both inflammatory and infectious diseases. It is also developing interleukin-1 alpha therapies to treat variety of medical...

Get notified when there are updates to the investment portfolio of D. E. Shaw & Co., Inc., based on Form 13F filings with the SEC.

Stay updated on D. E. Shaw & Co., Inc. with notifications on news.